Login
$GALT
$3.02 -$0.03 (0.98%) Live

$GALT 8-K/A SEC Filings

Filed On Filing
13 Nov 2023 8-K/A: Results of Operations and Financial Condition

NORCROSS, Georgia, November 13, 2023 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for ...

03 Jan 2019 8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

THIS FIRST AMENDMENT TO LINE OF CREDIT LETTER AGREEMENT (this “First Amendment”), dated as of December 20, 2018 (the “Amendment Date”), is entered into by and between Richard E. Uihlein, an individual resident of the State of Illinois (“...

19 Dec 2017 8-K/A: Submission of Matters to a Vote of Security Holders

At the 2017 Annual Meeting of Stockholders held on December 14, 2017, the stockholders of Galectin Therapeutics Inc. (“Galectin” or the “Company”) elected each of the Company’s directors that had been nominated to serve until the next an...

18 Aug 2017 8-K/A: Results of Operations and Financial Condition

NORCROSS, Ga., Aug. 18, 2017 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, is issuing this press release to provide clarification of the press release is...

30 Mar 2009 8-K/A: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

15 Feb 2008 8-K/A: Entry into a Material Definitive Agreement

This letter (the “Agreement”) constitutes the agreement between Maxim Group, LLC (“Maxim” or the “Placement Agent”) and Pro-Pharmaceuticals, Inc. (the “Company”), that Maxim shall serve as the placement agent for the Company, on a “reaso...

27 Sep 2007 8-K/A: Departure/Election of Directors or Officers; Compensation

This Employment Agreement (this “Agreement”) is made effective as of October 1, 2007, by and between Pro-Pharmaceuticals (“Pro-Pharmaceuticals”), of 7 Wells Avenue, Suite 34, Newton, Massachusetts, 02459 and Theodore D. Zucconi Ph.D. (“Z...

18 Sep 2002 8-K/A: Other Events

Pro-Pharmaceuticals, Inc. amends and restates its Current Report on Form 8-K filed September 5, 2002 as follows:

08 Mar 2002 8-K/A: Changes in Registrant's Certifying Accountant

Securities and Exchange Commission 450 5th Street, N.W. Washington, D.C. 20549

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support